ReviewJournal of clinical medicine2026
Therapeutic Targeting of VEGFR-2, PD-L1, and EGFR-MET Pathways in Non-Small Cell Lung Cancer: Clinical Progress with Ramucirumab, Atezolizumab, and Amivantamab.
Piotr Kawczak et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.